Lung cancer is the leading cause of cancer death worldwide, responsible for approximately 1.8 million deaths annually. Despite this, it is also one of the most treatable cancers when detected early. Advances in low-dose CT screening, molecular diagnostics, targeted therapy, and immunotherapy have fundamentally changed the outlook for many patients over the past decade. Shanghai sits at the forefront of these developments in Asia, offering international patients access to world-class diagnostic and treatment capabilities at a fraction of the cost of equivalent care in Western countries.
Types of Lung Cancer
Lung cancer is broadly divided into two major categories, which behave differently and require different treatment approaches:
- Non-Small Cell Lung Cancer (NSCLC): Accounts for approximately 85% of all lung cancers. Subtypes include adenocarcinoma (the most common, especially in non-smokers and women), squamous cell carcinoma, and large cell carcinoma. NSCLC is the primary focus of modern targeted therapy and immunotherapy development.
- Small Cell Lung Cancer (SCLC): Accounts for approximately 15% of cases. Strongly associated with smoking. Grows and spreads rapidly, often presenting at an advanced stage. Treated primarily with chemotherapy and immunotherapy; surgery plays a limited role.
Within NSCLC, molecular subtyping has become essential. Tumors are now routinely tested for driver mutations — genetic alterations that fuel cancer growth and, critically, can be targeted with specific drugs.
Key Driver Mutations in NSCLC
The identification of driver mutations has transformed lung cancer from a single disease into a collection of molecularly distinct subtypes, each with its own optimal treatment strategy. The most clinically important mutations include:
- EGFR (Epidermal Growth Factor Receptor): Present in approximately 10–15% of Western NSCLC patients and 40–60% of Asian patients with adenocarcinoma. EGFR-mutant tumors respond dramatically to EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib (third-generation), gefitinib, and erlotinib.
- ALK (Anaplastic Lymphoma Kinase) rearrangement: Found in approximately 3–5% of NSCLC cases. Highly sensitive to ALK inhibitors such as alectinib, brigatinib, and lorlatinib.
- ROS1 rearrangement: Present in 1–2% of cases. Responds to crizotinib and entrectinib.
- KRAS G12C mutation: Common in Western patients (approximately 13% of NSCLC). Sotorasib and adagrasib are now approved specifically for this mutation.
- MET exon 14 skipping: Found in 3–4% of cases. Targeted by capmatinib and tepotinib.
- RET rearrangement, BRAF V600E, HER2 mutation, NTRK fusion: Less common but each with approved targeted therapies.
Comprehensive molecular profiling — typically via next-generation sequencing (NGS) of tumor tissue or liquid biopsy — is standard practice at Shanghai's leading thoracic oncology centers and is essential before initiating systemic therapy for advanced NSCLC.
Lung Cancer Screening: Who Should Be Screened?
The majority of lung cancers are diagnosed at an advanced stage, when curative treatment is no longer possible. Screening high-risk individuals with low-dose CT (LDCT) has been shown to reduce lung cancer mortality by 20–24% in landmark trials (NLST, NELSON). Current international guidelines recommend annual LDCT screening for:
- Adults aged 50–80 years
- With a smoking history of ≥20 pack-years (one pack per day for 20 years, or equivalent)
- Who currently smoke or quit within the past 15 years
In China, where adenocarcinoma in non-smokers (particularly women) is disproportionately common, some guidelines extend screening recommendations to non-smokers with other risk factors such as occupational exposures, family history of lung cancer, or history of pulmonary fibrosis or COPD.
LDCT screening in Shanghai is widely available, affordable (typically USD 80–200 per scan), and can be arranged rapidly — often within 24–48 hours of arrival. Results are typically reported by experienced thoracic radiologists within 1–2 days.
Staging Lung Cancer
Lung cancer staging follows the TNM system (Tumor, Node, Metastasis), with stages I through IV:
- Stage I: Tumor confined to the lung, no lymph node involvement. Best candidates for curative surgery or stereotactic radiotherapy.
- Stage II: Tumor with limited regional lymph node involvement. Surgery with adjuvant chemotherapy or targeted therapy is standard.
- Stage III: Locally advanced disease with mediastinal lymph node involvement. Treatment typically involves concurrent chemoradiotherapy, often followed by consolidation immunotherapy (durvalumab).
- Stage IV: Metastatic disease. Treatment is systemic — targeted therapy (if driver mutation present), immunotherapy, or chemotherapy — with the goal of disease control and quality of life.
Accurate staging requires PET-CT (to assess metabolic activity and distant spread), brain MRI (to exclude cerebral metastases), and endobronchial ultrasound (EBUS) or mediastinoscopy for lymph node sampling when indicated. All of these are available at Shanghai's major thoracic centers.
Surgical Treatment
Surgery remains the cornerstone of curative treatment for early-stage NSCLC. The standard operation is a lobectomy — removal of the affected lobe of the lung — performed either via open thoracotomy or, increasingly, via video-assisted thoracoscopic surgery (VATS) or robotic-assisted thoracic surgery (RATS).
Minimally invasive approaches (VATS and RATS) offer significant advantages: smaller incisions, less postoperative pain, shorter hospital stays (typically 3–5 days versus 7–10 days for open surgery), and faster recovery. Shanghai's thoracic surgery departments at hospitals such as Shanghai Chest Hospital, Zhongshan Hospital, and Shanghai Pulmonary Hospital are among the highest-volume centers in the world for VATS lobectomy.
For patients with very small tumors (≤2 cm) or limited pulmonary reserve, sublobar resection (segmentectomy or wedge resection) may be appropriate. Recent trial data (JCOG0802, CALGB 140503) support segmentectomy as oncologically equivalent to lobectomy for tumors ≤2 cm with no lymph node involvement.
Adjuvant osimertinib (for EGFR-mutant stage IB–IIIA NSCLC) and adjuvant atezolizumab (for PD-L1-positive stage II–IIIA NSCLC) are now standard post-surgical options that have significantly improved disease-free survival.
Radiation Therapy
For patients with early-stage NSCLC who are not surgical candidates due to poor lung function or comorbidities, Stereotactic Body Radiotherapy (SBRT) — also called Stereotactic Ablative Radiotherapy (SABR) — delivers high-dose, precisely targeted radiation in 3–5 fractions. Local control rates with SBRT for stage I NSCLC exceed 90% at 3 years, comparable to surgery in many series.
For locally advanced (stage III) disease, concurrent chemoradiotherapy followed by 12 months of consolidation durvalumab (PACIFIC regimen) is the standard of care and is available at Shanghai's major oncology centers.
Proton beam therapy is available at select Shanghai facilities and may be preferred for tumors in challenging locations or in patients with limited pulmonary reserve, as it reduces radiation dose to surrounding healthy lung tissue.
Systemic Therapy: Targeted Agents
For patients with advanced NSCLC harboring a driver mutation, targeted therapy is dramatically more effective than chemotherapy and is the preferred first-line treatment. Key regimens include:
- Osimertinib (Tagrisso): Third-generation EGFR TKI, now the preferred first-line treatment for EGFR-mutant advanced NSCLC based on the FLAURA trial. Also active against T790M resistance mutations and CNS metastases.
- Alectinib (Alecensa): Preferred first-line ALK inhibitor based on the ALEX trial. Excellent CNS penetration.
- Lorlatinib: Third-generation ALK/ROS1 inhibitor with superior CNS activity, now preferred first-line in some guidelines based on CROWN trial data.
- Sotorasib / Adagrasib: First approved therapies specifically targeting KRAS G12C.
All major approved targeted agents are available in Shanghai, including some that may not yet be approved or reimbursed in the patient's home country. Access to clinical trials investigating next-generation targeted agents is also available at major centers.
Systemic Therapy: Immunotherapy
For patients without a targetable driver mutation, immunotherapy — particularly PD-1/PD-L1 checkpoint inhibitors — has become the backbone of first-line treatment for advanced NSCLC:
- High PD-L1 expression (≥50%): Pembrolizumab monotherapy (KEYNOTE-024) or pembrolizumab + chemotherapy.
- Any PD-L1 level: Pembrolizumab + platinum-based chemotherapy (KEYNOTE-189 for non-squamous; KEYNOTE-407 for squamous) is widely used.
- Nivolumab + ipilimumab ± chemotherapy: An alternative combination regimen (CheckMate 9LA, CheckMate 227).
PD-L1 testing and tumor mutational burden (TMB) assessment are routinely performed to guide immunotherapy selection. Immune-related adverse events require careful monitoring and management by experienced oncologists.
Brain Metastases
Lung cancer is one of the most common causes of brain metastases. Management has evolved significantly:
- For patients on EGFR or ALK targeted therapy, many modern agents (osimertinib, alectinib, lorlatinib) have excellent CNS penetration and can control brain metastases without immediate radiation.
- Stereotactic radiosurgery (SRS) — single-fraction high-dose radiation to individual brain metastases — is preferred over whole-brain radiotherapy for limited metastases (≤4–5 lesions) to preserve neurocognitive function.
- Whole-brain radiotherapy (WBRT) is reserved for patients with multiple or leptomeningeal metastases.
Shanghai's neurosurgery and radiation oncology departments are experienced in managing lung cancer brain metastases using both SRS (Gamma Knife, CyberKnife) and surgical resection for large or symptomatic lesions.
What Medical Records Are Required
To facilitate a specialist consultation in Shanghai, patients should prepare:
- CT scan of the chest (with contrast, ideally within 2–3 months) in DICOM format
- PET-CT report and images (if performed)
- Brain MRI (with contrast)
- Pathology report from bronchoscopy, CT-guided biopsy, or surgical specimen
- Molecular profiling / NGS report (EGFR, ALK, ROS1, KRAS, PD-L1, TMB, and other mutations tested)
- Pulmonary function tests (spirometry) if surgery is being considered
- Summary of prior treatments with response assessments
- Current medication list
Cost Reference
Indicative costs for lung cancer-related care in Shanghai:
- Low-dose CT screening: USD 80–200
- PET-CT scan: USD 800–1,500
- Bronchoscopy with EBUS: USD 1,000–2,500
- VATS lobectomy (including hospital stay): USD 12,000–25,000
- SBRT (full course): USD 4,000–8,000
- NGS molecular profiling: USD 500–1,500
- Targeted therapy (monthly, drug cost): USD 800–3,500 depending on agent
Costs vary by hospital tier, case complexity, and length of stay. A detailed estimate can be provided after medical record review.
Frequently Asked Questions
I am a non-smoker. Should I still be concerned about lung cancer?
Yes. Lung adenocarcinoma in non-smokers is increasingly recognized as a distinct disease entity, particularly prevalent in East Asian women. Risk factors include secondhand smoke exposure, radon, air pollution, occupational exposures, and genetic predisposition. If you have respiratory symptoms or a family history of lung cancer, discuss screening with your physician.
How quickly can I get a diagnosis in Shanghai?
For most patients, a CT scan can be arranged within 24–48 hours of arrival. Bronchoscopy or CT-guided biopsy can typically be scheduled within 3–5 days. NGS results from tissue samples are usually available within 7–14 days.
Can I access clinical trials in Shanghai?
Yes. Shanghai's major thoracic oncology centers participate in numerous international and China-specific clinical trials, including studies of novel targeted agents, next-generation immunotherapy combinations, and antibody-drug conjugates (ADCs). Eligibility depends on your specific diagnosis and prior treatment history.
What if I am already on targeted therapy in my home country?
Shanghai oncologists can continue your current regimen, perform resistance testing if your disease has progressed, and recommend next-line options. Bring documentation of your current drug, dose, start date, and any recent imaging showing response or progression.
Planning Your Care in Shanghai
If you are considering lung cancer screening or treatment in Shanghai, China Medical Concierge (CMCS) can coordinate your specialist consultation, hospital placement, translation, and travel logistics. Contact us to begin with a confidential review of your records.
0 Kommentare